'Remdesivir Not A Life Saver': AIIMS Chief

  • 3:57
  • Published On: April 24, 2021
Cinema View
Embed
Amid the scramble for the anti-viral drug remdesivir, AIIMS chief Dr Randeep Guleria clarifies on COVID-19 treatment protocol. He says remdesivir, if given for five days, can decrease hospital admissions, but does not reduce deaths. "There is mixed data about remdesivir's efficacy, that's why it's in emergency use category in India. It has side effects and should be given under medical supervision," Dr Guleria says.

Related Videos

AstraZeneca Initiates A Global Withdrawal Of Its Covid-19 Vaccine
May 08, 2024 2:12
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
May 08, 2024 2:54
AstraZeneca Withdraws Covid Vaccine, Cites Commercial Reasons: Report
May 08, 2024 0:45
AstraZeneca Covid 19 Vaccine Side Effects | What Is TTS, A Rare Condition Caused By Covishield
May 01, 2024 4:03
Astrazeneca's Big U-Turn, Admits Rare Blood Clot Risk
April 30, 2024 2:21
AstraZeneca Makes Big U-Turn, Admits Covishield Can Cause Rare Side Effects
April 30, 2024 2:48
"This Was Expected": Karnataka Health Minister On JN.1 Cases In State
December 25, 2023 3:57
Maharashtra Reports 50 New COVID-19 Cases, 9 Of Them JN.1 Infections
December 25, 2023 0:46
Top Headlines Of The Day: December 24, 2023
December 24, 2023 1:20
"No Need To Panic, Need To Remain Alert": AIIMS On JN.1 Covid Variant
December 24, 2023 4:52
All You Need To Know About The New COVID Variant JN.1
December 22, 2023 9:12
Another Pandemic In 25 Years? UN Body Report Warns Of Fallouts Of Climate Change
December 14, 2023 8:29
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination